Journal: Frontiers in Pharmacology

Article Title: Phosphodiesterase 7: a potential novel therapeutic target in ovarian cancer

doi: 10.3389/fphar.2025.1566330

Figure Lengend Snippet: Validation of gene expression by RT-qPCR. (A-I) The relative expression of genes in seven fallopian tube samples and seven samples from HGSC patients, as determined by RNA sequencing data, was validated using RT-qPCR.

Article Snippet: Amongst the first twenty genes from the high-throughput RNA sequencing data (data gently provided by Dr. Shih from Johns Hopkins University), we designed primers for nine of them.

Techniques: Biomarker Discovery, Gene Expression, Quantitative RT-PCR, Expressing, RNA Sequencing

Journal: Translational Oncology

Article Title: Decentralization of Next-Generation RNA Sequencing-Based MammaPrint® and BluePrint® Kit at University Hospitals Leuven and Curie Institute Paris

doi: 10.1016/j.tranon.2019.08.008

Figure Lengend Snippet: Patient sample inclusion diagram. Patient samples need to successfully pass different stages and quality controls before they can be included in the final analysis. Abbreviations: NGS, next-generation sequencing; QC, quality control; UHL, University Hospitals Leuven; CIP, Curie Institut Paris.

Article Snippet: In this beta testing study, we validated the Next-Generation RNA sequencing-based MP/BP NGS kit in UHL and CIP and we demonstrated reproducibility of the MP and BP NGS test between two independent decentralized laboratories and Agendia central laboratories.

Techniques: Next-Generation Sequencing

Journal: Translational Oncology

Article Title: Decentralization of Next-Generation RNA Sequencing-Based MammaPrint® and BluePrint® Kit at University Hospitals Leuven and Curie Institute Paris

doi: 10.1016/j.tranon.2019.08.008

Figure Lengend Snippet: MammaPrint (MP) microarray indices assessed at Agendia Amsterdam central laboratory in comparison to MP NGS indices at the beta sites. The comparison shows equivalence between the two technologies (Pearson's r = 0.96). The x-axis reports the MP microarray index, the y-axis reports the MP NGS index. Each dot represents a single breast cancer sample for which total RNA underwent microarray and NGS laboratory processing and analysis. The blue dots represent the discordant cases with indices close to the classification threshold.

Article Snippet: In this beta testing study, we validated the Next-Generation RNA sequencing-based MP/BP NGS kit in UHL and CIP and we demonstrated reproducibility of the MP and BP NGS test between two independent decentralized laboratories and Agendia central laboratories.

Techniques: Microarray

Journal: Translational Oncology

Article Title: Decentralization of Next-Generation RNA Sequencing-Based MammaPrint® and BluePrint® Kit at University Hospitals Leuven and Curie Institute Paris

doi: 10.1016/j.tranon.2019.08.008

Figure Lengend Snippet: Comparison of molecular subtyping using MP and BP tests (Luminal A for Low Risk MP and Luminal B for High Risk) between NGS Beta Site and IHC according to Prat et al. (n = 124) ( A ), between NGS Beta Site and IHC according to Maisonneuve et al. (n = 124) ( B ), between NGS Beta Site and microarray Agendia (n = 124) ( C ), and between NGS Beta Site and NGS Agendia (n = 114 ∗ ) ( D ). These results show a concordance of 71.8% (89/124) ( A ), 76.6% (95/124) ( B ), 89.5% (111/124) ( C ) and 93.9% (107/114) ( D ).

Article Snippet: In this beta testing study, we validated the Next-Generation RNA sequencing-based MP/BP NGS kit in UHL and CIP and we demonstrated reproducibility of the MP and BP NGS test between two independent decentralized laboratories and Agendia central laboratories.

Techniques: Microarray

Journal: Translational Oncology

Article Title: Decentralization of Next-Generation RNA Sequencing-Based MammaPrint® and BluePrint® Kit at University Hospitals Leuven and Curie Institute Paris

doi: 10.1016/j.tranon.2019.08.008

Figure Lengend Snippet: MammaPrint (MP) NGS indices assessed at Agendia Amsterdam central laboratory in comparison to MP NGS at the beta sites. The comparison shows equivalence between MP NGS performed at Agendia (x-axis) and MP NGS at the beta sites (y-axis) (Pearson's r = 0.96) (n = 114). Each dot represents a single breast cancer sample for which total RNA underwent NGS or microarray laboratory processing and analysis. Out of the 124 samples processed on NGS, 10 samples lacked NGS results at Agendia. The blue dots represent the discordant cases with indices close to the classification threshold.

Article Snippet: In this beta testing study, we validated the Next-Generation RNA sequencing-based MP/BP NGS kit in UHL and CIP and we demonstrated reproducibility of the MP and BP NGS test between two independent decentralized laboratories and Agendia central laboratories.

Techniques: Microarray